Pharmacokinetic/Pharmacodynamic of Albinterferon Alfa-2b in Chronic Hepatitis B, eAg+, Infection Subjects

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2009
This study will assess the efficacy of ABF656 in chronic hepatitis B characterized by HBeAg positivity. The study is designed to establish a dose response and safety relationship sufficient to allow the subsequent design and conduct of Phase 3 trials. The trial is also designed to generate the PK data in hepatitis B patients to satisfy regulatory requirements in China.
Epistemonikos ID: 5e9e9a99e19bee43cbac5223a384d610a1ad0231
First added on: Nov 24, 2021